# Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN

> **NCT05817955** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 50 (estimated)

## Conditions studied

- MDS/MPN

## Interventions

- **DRUG:** Azacitidine (AZA) with Ruxolitinib

## Key facts

- **NCT ID:** NCT05817955
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817955, "Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05817955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*